Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases

Arthritis and Rheumatism

Volumn 43, Issue 8, 2000, Pages 1891-1896

  Crofford, Leslie J ^e   Oates, Jim C ^b   McCune, W Joseph ^a   Gupta, Samardeep ^a   Kaplan, Mariana J ^a   Catella Lawson, Francesca ^c   Morrow, Jason D ^d   McDonagh, Kevin T ^a   Schmaier, Alvin H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; WARFARIN;

ADULT; ARTICLE; CASE REPORT; CONNECTIVE TISSUE DISEASE; ENCEPHALITIS; ENZYME INHIBITION; FEMALE; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOSIS; TREATMENT OUTCOME; VASOSPASM;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; CONNECTIVE TISSUE DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; THROMBOSIS;

EID: 0033898782     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200008)43:8<1891::AID-ANR28>3.0.CO;2-R     Document Type: Article

References (17)

1. Cyclooxygenase inhibition and thrombogenicity
2. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
3. Aspirin as an antiplatelet drug
4. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
5. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
6. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
7. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
8. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids
9. Human arterial and venous tissue generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation
10. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress
11. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
12. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells
13. Pathogenesis and treatment of the antiphospholipid antibody syndrome
14. Increased thromboxane formation in patients with antiphospholipid syndrome
15. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant
16. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus
17. Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome